NCT05690581招募中1 期
A Nonrandomized, Open-label, Multicenter, Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Subjects with Advanced Solid Tumors and Hematologic Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 146
- 试验地点
- 3
- 主要终点
- Adverse events (AEs)
研究概览
简要总结
This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic Malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Solid tumor Inclusion Criteria:
- •Life expectancy ≥12 weeks.
- •Eastern Cooperative Oncology Group performance status of 0-
- •Subjects with cytology and/or histologically confirmed locally advanced unresectable or metastatic solid tumors.
- •Agree to provide archived tumor tissue samples of primary or metastatic lesions.
- •Phase Ia: have at least one measurable lesion or one evaluable lesion according to RECIST 1.
- •Have adequate organ function as described in the protocol.
- •Hematologic Malignancies Inclusion Criteria:
- •Male and female subjects ≥18 years of age and ≤ 75 years of age.
- •This study enroll subjects with recurrent/refractory hematological tumors.
- •The subjects must have measurable lesions.
- •Positive CCR8in tumor tissues of subjects.
- •Eastern Cooperative Oncology Group performance status (ECOG) of ≤2, and had a Life expectancy of at least 3 months.
- •Adequate hematological function, defined as protocol.
- •Subjects with normal coagulation function, defined as protocol.
- •Adequate hepatic, renal and cardiac functions, defined as protocol.
- •Subjects voluntarily signed informed consent form (ICF) and written informed consent must be obtained prior to performing any study-related procedure.
- •Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to receiving the first dose of study medication.
- •WOCBP or male subjects and their female partners of childbearing potential must be willing to use an appropriate method of contraception during the study and for 6 months after the last dose, and must not donate eggs or sperms during this period.
- •Female subjects were not allowed to breastfeed during the study and for at least 6 months after the last dose of study medication.
排除标准
- •Solid tumor Exclusion Criteria:
- •Subjects with primary central nervous system (CNS) tumors or unstable CNS metastases.
- •Subjects who have uncontrollable or major cardiovascular disease refer to protocol.
- •Subjects who have an active autoimmune disease or have had an autoimmune disease with risk of recurrence.
- •Subjects who have active or history of interstitial lung disease or non-infectious pneumonia.
- •Subjects with any active infection requiring systemic treatment by intravenous infusion within 14 days prior to the first administration of the study drug.
- •HIV infection; Hepatitis C virus (HCV) antibody positive; HCV infection.
- •History of active bleeding within 2 months before screening, or bleeding symptoms associated with application of anticoagulant drugs or other interventions.
- •Have not recovered to CTCAE Grade 1 or better from the adverse events due to previous cancer therapies.
- •Subjects who received systemic immunosuppressive drugs within 14 days prior to the first administration of the study drug.
- •Subjects who require systemic treatment of corticosteroids or other immunosuppressive agents within 14 days prior to first dose.
- •Has a history of severe allergic reactions to monoclonal antibodies.
- •Subjects with any mental or cognitive impairment that may limit their understanding, implementation.
- •Hematologic Malignancies Exclusion Criteria:
- •Previous treatment with immune checkpoint inhibitors
- •Autologous hematopoietic stem cell transplantation within 100 days prior to first investigational medications dose, or history of allogeneic hematopoietic stem cell transplantation.
- •Subjects currently suffering from acute graft-versus-host disease (GVHD) or active chronic GVHD.
- •Have had any therapy directed against the subject's underlying cancer within 28 days prior to first investigational medications dose.
- •Received other clinical trial drugs within 28 days prior to first investigational medications dose.
- •Subjects who experienced major organ surgery (except for needle biopsy) or significant trauma within 28 days prior to first investigational medications administration, or who need selected surgical procedures during the study.
- •Subjects who have been vaccinated with live attenuated vaccine within 28 days prior to first investigational medications administration.
- •Clinical evidence of central nervous system (CNS) metastasis will be excluded.
- •Previous or concomitant with CNS diseases.
- •History of another primary malignancy not in remission for at least 2 years.
- •Any severe active infection requiring systemic antimicrobial therapy.
- •Active hepatitis B or C virus infection.
- •History of immunodeficiency, including human immunodeficiency virus (HIV) antibody positive or known syphilis infection.
- •History of severe cardiovascular and cerebrovascular diseases.
- •Subjects who currently or have suffered from severe interstitial lung disease.
- •The toxicity of previous anti-tumor therapy is still ≥ grade 2 at enrollment.
- •History of severe bleeding disorders,.
- •Known alcohol or drug dependence.
- •Subjects with mental disorders or poor compliance.
- •Pregnant or lactating female subjects.
- •Any other condition that, in the opinion of the investigator or project clinician, would interfere with a subject's ability to receive or complete the study.
研究组 & 干预措施
CM369 Ia Dose Escalation
Experimental
Dose escalation of CM369 as monotherapy
干预措施: CM369 (Drug)
CM369 Ib Dose Expansion
Experimental
Dose expansion of CM369 as monotherapy
干预措施: CM369 (Drug)
结局指标
主要结局
Adverse events (AEs)
时间窗: 90 weeks
Serious Adverse events (SAEs)
时间窗: 90 weeks
Dose limiting toxicities (DLTs)
时间窗: 90 weeks
次要结局
- PK parameter: Peak Time (Tmax)(90 weeks)
- PK parameter: Half-life (t1/2)(90 weeks)
- PK parameter: Area Under the Curve (AUC)(90 weeks)
- PK parameters: Clearance (CL)(90 weeks)
- PK parameter: Apparent volume of distribution of steady state (Vss)(90 weeks)
- Immunogenicity: Incidence of anti-CM369 antibody(90 weeks)
研究者
研究点 (3)
Loading locations...
相似试验
终止
1 期
A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)Advanced Hepatocellular CarcinomaNCT01942083Korea Otsuka Pharmaceutical Co., Ltd.33
已完成
1 期
Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)Nosocomial PneumoniaNCT04223752Merck Sharp & Dohme LLC41
Unknown
1 期
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.Nasopharyngeal CarcinomaNCT04073784Sun Yat-sen University41
招募中
1 期
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid TumorsSolid TumorsNCT05650242Shandong Boan Biotechnology Co., Ltd177
已完成
1 期
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib TreatmentNon-Small-Cell Lung CarcinomaNCT01801111Hoffmann-La Roche138